Biotech Values

[iwfal]

RVX - "In patients with low HDL receiving RVX-208 and Rosuvastatin (Crestor(R) ), plaque regression was twice as pronounced as compared to the pre-specified primary endpoint."

Reminder that most of their commentary about this trial has been about results in the Statin+208 arm vs baseline. Not placebo controlled. And we know Rosuvastatin (and, to a lesser extent, Atorvastatin) at these and higher doses have been shown to (sometimes? always?) produce regression (and increased HDL). So if 208 has efficacy in this regard you will only be able to tell by comparison to the statin + placebo arm.


And yet all of their comparisons regarding regression are to baseline - not placebo. (I understand that the placebo arm was particulary small - but nonetheless suggest that they shouldn't get a free pass just because they chose to have minimal placebo arm).